The State University of New York

Brookhaven Science Associates, Lcc

Baxalta Gmbh

University of Rochester

Other

Baxter International Inc.

Baxter Healthcare Sa

Brook Biotechnologies, Inc.

Brook Biotechnology, Inc.

Benjamin J Luft

John J Dunn

Raymond J Dattwyler

Maria J C Gomes-Solecki

Ian Livey

Michael Schwendinger

Brian A Crowe

Maria O'Rourke

Shohei Koide

Catherine L Lawson

Maria Gomes-Solecki

Gerald Seinost

Daniel Dykhuizen

Maria O'rourke

The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety ofgenospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.

Chimeric OspA genes, proteins and methods of use thereof

Chimeric OspA proteins and methods of use thereof

Provided herein are OspA polypeptides from Lyme Disease-causinghaving certain alteration(s). In one embodiment, the alteration(s) increase the conformational stability of the OspA polypeptide containing the alteration(s) while maintaining at least some of the antigenicity of the corresponding unaltered OspA polypeptide. In another embodiment, the altered OspA polypeptide has reduced cross-reactivity to hLFA-1, as compared to the corresponding unaltered OspA polypeptide.

[object Object]

The invention relates to the development of chimeric OpsA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety ofgenospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.

Chimeric OspA genes, proteins, and methods of use thereof

Novel chimeric nucleic acids, encoding chimericproteins comprising OspC or an antigenic fragment thereof and OspA or an antigenic fragment thereof, are disclosed. Chimeric proteins encoded by the nucleic acid sequences are also disclosed. The chimeric proteins are useful as vaccine immunogens against Lyme borreliosis, as well as for immunodiagnostic reagents.

The present invention is drawn to an immunogenic composition comprising OspC polypeptides from Lyme Disease causingIn one embodiment, the immunogenic composition of the present invention comprises at least one OspC polypeptide or immunogenic fragment thereof from each ofOspC families A, B, I and K. In another embodiment, the immunogenic composition of the present invention comprises at least one OspC polypeptide or immunogenic fragment thereof from each ofOspC families A and B.

The present invention is drawn to an immunogenic composition comprising OspC polypeptides from Lyme Disease causing. In one embodiment, the immunogenic composition of the present invention comprises at least one OspC polypeptide or immunogenic fragment thereof from each ofOspC families A, B, I and K. In another embodiment, the immunogenic composition of the present invention comprises at least one OspC polypeptide or immunogenic fragment thereof from each ofOspC families A and B.

Recombinant constructs of Borrelia burgdorferi

Chimeric nucleic acids encoding chimeric Borrelia proteins consisting of at least two antigenic polypeptides from corresponding and/or non-corresponding proteins from the same and/or different species of Borrelia, are disclosed. Chimeric proteins encoded by the nucleic acid sequences are also disclosed. The chimeric proteins are useful as vaccine immunogens against Lyme borreliosis, as well as for immunodiagnostic reagents.

Chimeric proteins comprising borrelia polypeptides and uses therefor

Growing community of inventors

Riverhead, NY, United States of America

Benjamin J Luft